

VANTRELA ER - (15MG, 30MG, 45MG, 60MG, 90MG ; TABLET,EXTENDED RELEASE)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | HYDROCODONE BITARTRATE | Innovator | Teva |
| Dosage | 15MG, 30MG, 45MG, 60MG, 90MG ; TABLET,EXTENDED RELEASE | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | VANTRELA ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.